Global Navigation

Sub Men

Not currently logged in

Pharmacopeia makes senior additions to management

Pharmacopeia appoints a new executive vice-president of corporate development and senior vice-president of chemistry and preclinical chemical development

Pharmacopeia, a US-based small molecule drug developer, has appointed Eric J Liebler as its executive vice-president of corporate development and Dr S David Kimball, as its senior vice-president of chemistry and preclinical chemical development.

Liebler will employ his broad experience in strategy and corporate development to refine Pharmacopeia's progress toward product commercialisation.

Prior to joining Pharmacopeia, Liebler served as senior vice-president of strategic Planning at Questcor and held executive-level positions with Enzon, Elan, Amarin and Athena Neurosciences. He currently serves as vice-chairman of the board of trustees of the American Academy of Neurology Foundation.

Kimball joins with more than 25 years of experience in drug discovery and will be responsible for all aspects of alliance and independent chemistry research and preclinical chemical development from target identification to investigational new drug (IND) submission. He will also serve as a key participant in the leadership of all alliances.

Before his Pharmacopeia appointment, Kimball was vice-president of medicinal chemistry at Lexicon. He oversaw a department of more than 70 scientists which executed broad-ranging activities including analytical, structural and computational, process and medicinal chemistry.

Kimball spent nearly 20 years at Bristol-Myers Squibb (BMS) Pharmaceutical Research Institute. In various research roles at BMS, he oversaw drug discovery and development projects in the areas of cardiovascular disease and oncology.

30th September 2008